業界のプレスリリース
02 Feb 2018
The FDA/CDER/OPQ mission is to ensure that safe, effective, high quality drugs are available for the American public. Established in 2015, OPQ encourages and supports development and adoption of emerging technology to modernize pharmaceutical development and manufacturing.
In development, scientist and engineers need to investigate the capability of their processes and develop strategies to avoid or manage the effects variability from various sources. The GEA ConsiGma™ 1 enables development of granules following QbD principles via fast DOE approaches with controlled continuous operation, providing an opportunity to explore a wider range of process parameters with less product and less time. The result is much better process understanding in a shorter time and with lower costs.
Media Relations
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468
Düsseldorf
Germany
+49 211 9136-0
GEA は、世界レベルの食品製造プロセス技術を有するとともに、乳業、飲料、パーソナル・ホームケア、化学など食品以外の幅広い分野にも実績があり、2019年度の連結売上高は約49億ユーロとなりました。